Tipranavir

Results: 69



#Item
31Beneficiary’s Medicaid ID#

Beneficiary’s Medicaid ID#

Add to Reading List

Source URL: ahca.myflorida.com

Language: English - Date: 2014-06-04 16:23:20
32CLINICAL REVIEW Application Type[removed]Submission Number 022 Submission Code SE5

CLINICAL REVIEW Application Type[removed]Submission Number 022 Submission Code SE5

Add to Reading List

Source URL: www.fda.gov

Language: English
33sbd_smd_2006_aptivus_098651_e.doc

sbd_smd_2006_aptivus_098651_e.doc

Add to Reading List

Source URL: hc-sc.gc.ca

Language: English - Date: 2013-07-12 14:26:14
34Beneficiary’s Medicaid ID#

Beneficiary’s Medicaid ID#

Add to Reading List

Source URL: www.fdhc.state.fl.us

Language: English - Date: 2014-06-04 16:23:20
35HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APTIVUS safely and effectively. See full prescribing information for APTIVUS. APTIVUS® (tipranavir) capsules APTIVU

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APTIVUS safely and effectively. See full prescribing information for APTIVUS. APTIVUS® (tipranavir) capsules APTIVU

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:10:23
36HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APTIVUS safely and effectively. See full prescribing information for APTIVUS. APTIVUS® (tipranavir) capsules APTIVU

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APTIVUS safely and effectively. See full prescribing information for APTIVUS. APTIVUS® (tipranavir) capsules APTIVU

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-05-07 12:26:46
37NDA[removed]S003 NDA[removed]S004 -4–  PREZISTA™* (Tibotec, Inc.)

NDA[removed]S003 NDA[removed]S004 -4– PREZISTA™* (Tibotec, Inc.)

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:10:39
38Abbreviated Process for PAC- No Presentation Full Safety Review Provided in Briefing Packet Zetia (ezetimibe) /Vytorin (ezetimibe/simvastatin) Aptivus (tipranavir)

Abbreviated Process for PAC- No Presentation Full Safety Review Provided in Briefing Packet Zetia (ezetimibe) /Vytorin (ezetimibe/simvastatin) Aptivus (tipranavir)

Add to Reading List

Source URL: www.fda.gov

    39HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NORVIR safely and effectively. See full prescribing information for NORVIR. NORVIR (ritonavir) Tablet for Oral use

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NORVIR safely and effectively. See full prescribing information for NORVIR. NORVIR (ritonavir) Tablet for Oral use

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2012-02-22 15:55:19
    40HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE.  

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2012-02-22 15:55:22